Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
HOUSTON, Nov. 08, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15 at 9:20 a.m. GMT in London, UK.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including allogeneic hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
[email protected]
Media:
BMC Communications
Brad Miles
646-513-3125
[email protected]
Source: Bellicum Pharmaceuticals
